Our portfolio

In vivo gene therapy

Ensoma is a preclinical in vivo gene therapy company that is focused on the targeting and editing of hematopoietic stem cells. The foundation envisions a future in which the company's technology could create a single shot HIV cure.
Website
  • Domain
    Life Sciences
  • Investment type
    Direct equity
  • Status
    Active
  • Initial investment
    Series B
  • Partnered in
    2022
  • Investment lead
    Vanessa Bhark
  • Headquarters
    USA
  • Program strategy
    HIV

More about our work

Our focus

Our six domains of focus comprise 40+ program strategies across the Foundation’s nearly $9B annual charitable support.

Investment approach

Fostering partnerships with the private sector to leverage groundbreaking global innovations for societal good.

Our team

We bring depth of experience to every investment, with a proven track record across sectors and scale.